A novel inhibitor of antiapoptotic BCL-2 proteins; a new promising anticancer drug candidate. Potent Bcl-2 family inhibitor.||Synonyms:|4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide; Navitoclax| |CAS NO:|923564-51-6||Molecular Formula:|C₄₇H₅₅ClF₃N₅O₆S₃||Molecular Weight:|974.61||Purity:|≥98%||Appearance:|Pale yellow to pale brown solid||Melting Point:|>124°C (dec.)||Solubility:|DMSO (slightly), Methanol (slightly)||Method for Determining Identity: |Proton NMR (DMSO-d6), 19F NMR (DMSO-d6) Spectroscopic and Mass Spectrometric Analysis||Atmosphere:|Inert gas||Ethyl Acetate Content:|~2.5%||Storage and Stability:|Powder may be stored at -20°C. Stable for 6 months after receipt at -20°C. Hygroscopic. Note: Inert atmosphere is preferred for long term storage.